Form 4 for TVRD Tvardi Therapeutics, Inc.
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-25 · accession 0001209191-22-013992 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-01 | 2022-02-25+ | TVRD | Reilly Thomas Charles | CFO | A - Grant | $2.17 | +25.3K | 34.5K | +276% | +$54.9K |
| D | 2022-03-01 | 2022-02-25 | TVRD | Reilly Thomas Charles | CFO | A - Grant | $0.00 | +40.0K | 40.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-28 | A | A | 5,333 | $10.29 | 39,855 | D | — | — | (F2) Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 28, 2022. The vested shares represents the last of three possible vesting events of the total number of shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer. |
| 2 | Common | Common Stock | 2022-02-25 | A | A | 20,000 | $0.00 | 34,522 | D | — | — | (F1) Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2022-02-25 | A | A | 40,000 | $0.00 | 40,000 | D | $10.46 · — to 2032-02-25 | 40,000 Common Stock | (F3) The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date. |